PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES OF ASSOCIATES OF COPPER NANOPARTICLES
- Autores: Borodulin V.B.1, Matasov A.D.2,3, Goroshinskaya I.A.4, Okunev I.S.2, Petrov S.N.5, Drozdova N.F.5, Kachesova P.S.4, Losev O.E.1, Bobyleva E.V.1, Zlatnik E.Y.4, Chebotareva E.G.1, Lazarenko Y.S.1, Bobylev A.V.1, Borodulina E.V.1
-
Afiliações:
- Saratov State Medical University, Russian Ministry of Health
- Konstantinov St. Petersburg Institute of Nuclear Physics
- Ioffe Institute
- Rostov Research Institute of Oncology, Russian Ministry of Health
- Prometey
- Edição: Volume 14, Nº 1-2 (2019)
- Páginas: 74-81
- Seção: Nanobiomedicine and Nanopharmaceuticals
- URL: https://journals.rcsi.science/2635-1676/article/view/220724
- DOI: https://doi.org/10.1134/S1995078019010038
- ID: 220724
Citar
Resumo
Abstract—The physicochemical parameters of associates of unstabilized copper nanoparticles (NPs) obtained by the plasma-chemical method were studied. Optical methods were used to determine the size of NP associates, including atomic force microscopy, spectrophotometry, and fluorometry. The sizes of copper NPs varied from 30 to 75 nm, and the sizes of NP associates, from 481.1 to 1037 nm. The phase composition of copper NPs was analyzed by X-ray diffractometry using a Rigaku Ultima IV multifunctional X-ray diffractometer. An oxide film without an admixture of organic molecules was found on the surface of NP associates. The effect of copper NPs on an A549 cell culture was studied. A change was observed in the biochemical parameters of blood serum of outbred mice under the influence of copper NPs. The antitumor effect of copper NPs was revealed, and its intensity was compared to different methods of administering NP to animals with fibrosarcoma (S-45) and Pliss lymphosarcoma.
Sobre autores
V. Borodulin
Saratov State Medical University, Russian Ministry of Health
Autor responsável pela correspondência
Email: borodulinvb@mail.ru
Rússia, Saratov
A. Matasov
Konstantinov St. Petersburg Institute of Nuclear Physics; Ioffe Institute
Email: borodulinvb@mail.ru
Rússia, St. Petersburg; St. Petersburg
I. Goroshinskaya
Rostov Research Institute of Oncology, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Rostov-on-Don
I. Okunev
Konstantinov St. Petersburg Institute of Nuclear Physics
Email: borodulinvb@mail.ru
Rússia, St. Petersburg
S. Petrov
Prometey
Email: borodulinvb@mail.ru
Rússia, St. Petersburg
N. Drozdova
Prometey
Email: borodulinvb@mail.ru
Rússia, St. Petersburg
P. Kachesova
Rostov Research Institute of Oncology, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Rostov-on-Don
O. Losev
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
E. Bobyleva
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
E. Zlatnik
Rostov Research Institute of Oncology, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Rostov-on-Don
E. Chebotareva
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
Ya. Lazarenko
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
A. Bobylev
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
E. Borodulina
Saratov State Medical University, Russian Ministry of Health
Email: borodulinvb@mail.ru
Rússia, Saratov
Arquivos suplementares
